| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel
|
Xu, Chao
|
|
2018
|
82 |
3 |
p. 395-406
|
article
|
| 2 |
A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib
|
Ju, Lixia
|
|
2018
|
82 |
3 |
p. 561-564
|
article
|
| 3 |
An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors
|
Furuse, Junji
|
|
2018
|
82 |
3 |
p. 511-519
|
article
|
| 4 |
An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer
|
Belderbos, Bodine P. S. I.
|
|
2018
|
82 |
3 |
p. 457-468
|
article
|
| 5 |
A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors
|
Malik, Laeeq
|
|
2018
|
82 |
3 |
p. 533-539
|
article
|
| 6 |
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer
|
Patnaik, Amita
|
|
2018
|
82 |
3 |
p. 407-418
|
article
|
| 7 |
A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors
|
Wood, Paul J.
|
|
2018
|
82 |
3 |
p. 493-503
|
article
|
| 8 |
A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies
|
Harding, James J.
|
|
2018
|
82 |
3 |
p. 429-440
|
article
|
| 9 |
A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat
|
Peer, Cody J.
|
|
2018
|
82 |
3 |
p. 565-570
|
article
|
| 10 |
A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies
|
Das, Millie
|
|
|
82 |
3 |
p. 541-550
|
article
|
| 11 |
A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies
|
Das, Millie
|
|
2018
|
82 |
3 |
p. 541-550
|
article
|
| 12 |
Brazilin induces FOXO3A-dependent autophagic cell death by disturbing calcium homeostasis in osteosarcoma cells
|
Kang, Yan
|
|
2018
|
82 |
3 |
p. 479-491
|
article
|
| 13 |
Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer
|
Patnaik, Amita
|
|
2018
|
82 |
3 |
p. 419
|
article
|
| 14 |
Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation
|
Liao, Dehua
|
|
2018
|
82 |
3 |
p. 551-559
|
article
|
| 15 |
Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma
|
Chen, Guofu
|
|
2018
|
82 |
3 |
p. 505-510
|
article
|
| 16 |
Genetic polymorphisms in cyclin H gene are associated with oxaliplatin-induced acute peripheral neuropathy in South Indian digestive tract cancer patients
|
Palugulla, Sreenivasulu
|
|
2018
|
82 |
3 |
p. 421-428
|
article
|
| 17 |
Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer
|
Guo, Xiao-fang
|
|
2018
|
82 |
3 |
p. 383-394
|
article
|
| 18 |
Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin
|
Andel, L. van
|
|
2018
|
82 |
3 |
p. 441-455
|
article
|
| 19 |
Natural low- and high-density lipoproteins as mighty bio-nanocarriers for anticancer drug delivery
|
Mahmoudian, Mohammad
|
|
2018
|
82 |
3 |
p. 371-382
|
article
|
| 20 |
Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis
|
Choi, Jong Hwan
|
|
2018
|
82 |
3 |
p. 469-478
|
article
|
| 21 |
Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil® or Caelyx® in advanced ovarian cancer
|
Bhowmik, Shravanti
|
|
2018
|
82 |
3 |
p. 521-532
|
article
|
Journal description